Nexodyn AcidOxidizing Solution is a sprayable active cleanser with ancillary antimicrobial activity developed for acute and chronic wound management, and intended for use in the debridement, irrigation, cleansing, and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, vascular ulcers), post-surgical wounds, burns, and other lesions.
The pilot study, conducted with a prospective, single-arm design, engaged 30 patients with critically colonized or locally infected chronic leg ulcers of any origin.
Nexodyn AcidOxidizing Solution was applied on each leg ulcer at every dress change for 35 days together with a nonadherent gauze and a multi-purpose absorbent dressing. By the end of the study period, treatment with Nexodyn AcidOxidizing Solution led to the full healing of 37% of the chronic wounds as well as to a significant decrease in wound size.
Additionally, wound-associated infections were eliminated, together with a reduction in pH values and local bioburden covering the wound, whilst no reinfection of any examined wounds was observed during the study.
Results suggest that, due to its synergic and distinctive physico-chemical properties, the cleanser could play a role in the management of chronic wounds as it effectively promotes wound rebooting by creating the ideal microenvironment to sustain the physiological healing process and favors an optimized lesion closure.
Data also confirm a favorable safety and tolerability profile, especially relevant in chronic wounds, with no adverse events reported over the study duration, high levels of pain relief and comfort at application, as well as wound-associated pain reduction.
APR develops science driven, patent protected healthcare products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis.
The company is currently focused on internally developed and financed proprietary products to be licensed to healthcare companies for their commercialization, and support to third party projects by offering added value R and D services under contract and fee for service arrangements.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes